IL-12 Genetically Engineered Myeloid Cells for Cancer

This trial explores a new cancer treatment using genetically modified immune cells, called IL-12 GEMys, to enhance the body's cancer-fighting ability. Researchers are testing whether these cells can effectively target and kill cancer cells in solid tumors. The trial is open to individuals whose cancer has returned or did not respond to previous treatments. Participants will have their blood cells collected, modified to produce IL-12, and then infused back into their bodies. The goal is to determine if this approach can better control or eliminate the cancer. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial information does not specify if you need to stop taking your current medications. However, it mentions that a certain amount of time must pass since any systemic anti-cancer therapy before starting the trial, which might imply a need to pause some treatments. It's best to discuss your specific medications with the trial team.

In studies with mice, specially modified immune cells called IL-12 GEMys have shown promise in shrinking tumors and preventing cancer from spreading. These modified cells enhance the body's immune response against cancer. However, researchers are still testing their safety in humans. The treatment is in an early trial phase, marking one of the first times it is being tried in people. This phase is crucial for assessing how well people tolerate it and identifying any possible side effects. While these early trials are important, they do not yet offer complete safety information for humans. Participants should discuss potential risks and benefits with their doctors.¹²³⁴⁵

Researchers are excited about IL-12 GEMys because it represents a novel approach to cancer treatment by using genetically engineered myeloid cells. Unlike conventional treatments such as chemotherapy or radiation, which broadly target rapidly dividing cells, IL-12 GEMys specifically enhances the immune system's ability to fight cancer. This treatment works by delivering the IL-12 cytokine directly through modified cells, potentially leading to more precise targeting of cancer cells with reduced side effects. Additionally, the flexibility of dosing—escalating, de-escalating, or at the recommended Phase 2 dose (RP2D)—offers a tailored approach that could improve patient outcomes.

Research has shown that specially modified immune cells, called IL-12 GEMys, can effectively attack cancer cells. In studies with mice, these cells shrank tumors and extended the mice's lifespan compared to treatments without IL-12. This trial will test IL-12 GEMys in two different arms: one with escalating/de-escalating doses and another with the recommended phase 2 dose (RP2D), both with or without conditioning chemotherapy using cyclophosphamide and fludarabine. This treatment strengthens the immune system by enhancing T cell function, which is crucial for fighting tumors. Evidence also suggests that using IL-12 GEMys with chemotherapy might help prevent cancer recurrence. While these results are promising in animals, further research is needed to determine their effectiveness in humans.¹³⁵⁶⁷